# US 8,771,680 B2 · Topical co-enzyme Q10 formulations and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,771,680 B2
- Document ID: US8771680B2
- Status: Granted
- Kind: B2
- Application number: 14/031,706
- Filed: 2013-09-19
- Published: 2014-01-23
- Granted: 2014-07-08
- Earliest claimed: 2004-01-22
- Assignees: University of Miami
- Applicants: University of Miami
- Inventors: Sung Lan Hsia; Niven Rajin Narain; Jie Li; Kathryn J. Russell; Karrune V. Woan; Indushekhar Persaud
- Web page: https://patentgrep.com/patent/US8771680B2

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/351: not condensed with another ring
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/00: Drugs for dermatological disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Topical formulations of CoQ10 reduce the rate of tumor growth in an animcal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.

## Claims

### Claim 1

A method of treating a cancer in a subject, comprising:
administering to a subject in need thereof, a composition comprising 1% to 25% w/w of Coenzyme Q10; contacting at least one tumor cell with the composition in sufficient amounts and for a sufficient time to slow the growth of the tumor cell; thereby treating the cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises 1% to 20% w/w of Coenzyme Q10.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition comprising the Coenzyme Q10 is formulated as a topical cream.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprising Coenzyme Q10 is administered with one or more additional anti-cancer agents.

### Claim 5 (depends on 4)

The method of claim 4, wherein the additional anti-cancer agent is co-administered with the composition comprising Coenzyme Q10 to the subject.

### Claim 6 (depends on 4)

The method of claim 4, wherein administration of the additional anti-cancer agent precedes administration of the composition comprising Coenzyme Q10 to the subject.

### Claim 7 (depends on 4)

The method of claim 4, wherein administration of the additional anti-cancer agent follows administration of the composition comprising Coenzyme Q10 to the subject.

### Claim 8 (depends on 4)

The method of claim 4, wherein the additional anti-cancer agent is an anti-angiogenic agent.

### Claim 9 (depends on 4)

The method of claim 4, wherein the additional anti-cancer agent is a chemotherapeutic agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the chemotherapeutic agent is selected from the group consisting of cyclophosphamide, taxanes, busulfan, methotrexate, daunorubicin, doxorubicin, melphalan, cladribine, vincristine, vinblastine, chlorambucil, tamoxifen, taxol, camptothecin, actinomycin-D, mitomycin C, combretastatin, cisplatin, etoposide, verapamil, podophyllotoxin, and 5-fluorouracil.

### Claim 11 (depends on 10)

The method of claim 10, wherein the taxane is paclitaxel or docetaxel.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is a human subject.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition comprising the Coenzyme Q10 is formulated for intravenous administration.